Abstract
The use of drug-eluting coronary stents has led to significant reduction in in-stent restenosis (ISR), but led to delayed endothelialization, necessitating the prolonged use of expensive anti-thrombotic drugs with their side-effects. Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin. Our previous work in vitro has demonstrated; that the smooth muscle cells were inhibited significantly more than endothelial cells which is the desirable feature of an anti-restenosis drug. This work reports the effects of implantation of a centeritide-eluting stent (CES) on ISR and endothelialization in an in vivo model. CESs were produced by coating bare metallic stents with CD-NP entrapped in biodegradable poly(ε-caprolactone) using an ultrasonic spray coater. A total of 32 stents were successfully implanted into 16 pigs, and all animal survived for 28 days. The plasma levels of CD-NP were significantly higher in the CES group than in the control group (bare metal stents and polymer-coated stent) at post-stenting, indicating the successful release of CD-NP from the stent in vivo. Furthermore, SEM analysis results showed the greater endothelial coverage of the stent struts, as well as between the struts in CES group. Moreover, histological results showed mild inflammation, and low fibrin score at 28 days. However, plasma cGMP (second messenger, cyclic 3′,5′ guanosine monophosphate) does not show a significant difference, and the CES is also unable to show significant difference in terms on neointimal area and stenosis, in comparison to BMS at 28 days.
Similar content being viewed by others
References
Abassi, Z., T. Karram, S. Ellaham, J. Winaver, and A. Hoffman. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol. Ther. 102:223–241, 2004.
Barr, C. S., P. Rhodes, and A. D. Struthers. C-type natriuretic peptide. Peptides 17:1243–1251, 1996.
Carter, A. J., A. Brodeur, R. Collingwood, S. Ross, L. Gibson, C. A. Wang, S. Haller, L. Coleman, and R. Virmani. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter. Cardiovasc. Interv. 68:97–103, 2006.
Chen, H., and J. Burnett. Clinical application of the natriuretic peptides in heart failure. Eur. Heart J. Suppl. 8:E18–E25, 2006.
Degertekin, M., P. W. Serruys, D. P. Foley, K. Tanabe, E. Regar, J. Vos, P. C. Smits, W. J. van der Giessen, M. van den Brand, P. de Feyter, and J. J. Popma. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 106:1610–1613, 2002.
Del Ry, S., M. Maltinti, M. Emdin, C. Passino, G. Catapano, and D. Giannessi. Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clin. Chem. Lab. Med. 43:641–645, 2005.
Dickey, D. M., and L. R. Potter. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J. Mol. Cell. Cardiol. 51:67–71, 2011.
Furuya, M., Y. Tawaragi, Y. Minamitake, Y. Kitajima, K. Fuchimura, S. Tanaka, N. Minamino, K. Kangawa, and H. Matsuo. Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 183:964–969, 1992.
Furuya, M., M. Yoshida, Y. Hayashi, N. Ohnuma, N. Minamino, K. Kangawa, and H. Matsuo. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177:927–931, 1991.
Grube, E., S. Sonoda, F. Ikeno, Y. Honda, S. Kar, C. Chan, U. Gerckens, A. J. Lansky, and P. J. Fitzgerald. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109:2168–2171, 2004.
Hong, M. K., R. Kornowski, O. Bramwell, A. O. Ragheb, and M. B. Leon. Paclitaxel-coated Gianturco-Roubin (R) IIAl (GR (R) II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron. Artery Dis. 12:513–515, 2001.
Huang, Y., H. C. Ng, X. W. Ng, and V. Subbu. Drug-eluting biostable and erodible stents. J Control Release 193:188–201, 2014.
Huang, Y. Y., S. S. Venkatraman, F. Y. C. Boey, E. M. Lahti, P. R. Umashankar, M. Mohanty, S. Arumugam, L. Khanolkar, and S. Vaishnav. In vitro and in vivo performance of a dual drug-eluting stent (DDES). Biomaterials 31:4382–4391, 2010.
Huang, Y., S. S. Venkatraman, F. Y. C. Boey, P. R. Umashankar, M. Mohanty, and S. Arumugam. The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model. J. Interv. Cardiol. 22:466–478, 2009.
Jabara, R., N. Chronos, F. Tondato, D. Conway, W. Molema, K. Park, T. Mabin, S. King, and K. Robinson. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. J. Invasive Cardiol. 18:383–390, 2006.
Kalra, P. R., S. D. Anker, A. D. Struthers, and A. J. Coats. The role of C-type natriuretic peptide in cardiovascular medicine. Eur. Heart J. 22:997–1007, 2001.
Kedia, G., and M. S. Lee. Stent thrombosis with drug-eluting stents: A re-examination of the evidence. Catheter. Cardiovasc. Interv. 69:782–789, 2007.
Kereiakes, D. J., D. A. Cox, J. B. Hermiller, M. G. Midei, W. B. Bachinsky, E. D. Nukta, M. B. Leon, S. Fink, L. Marin, and A. J. Lansky. Usefulness of a cobalt chromium coronary stent alloy. Am. J. Cardiol. 92:463–466, 2003.
Lim, S. G., S. S. Venkatraman, J. C. Burnett, Jr, and H. H. Chen. In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. PLoS One 8:18, 2013.
Lisy, O., B. K. Huntley, D. J. McCormick, P. A. Kurlansky, and J. C. Burnett, Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 52:60–68, 2008.
Liu, K. L., E. Widjaja, Y. Huang, X. W. Ng, S. C. Loo, F. Y. Boey, and S. S. Venkatraman. A new insight for an old system: protein-PEG colocalization in relation to protein release from PCL/PEG blends. Mol. Pharm. 8:2173–2182, 2011.
Nakazawa, G., J. F. Granada, C. L. Alviar, A. Tellez, G. L. Kaluza, M. Y. Guilhermier, S. Parker, S. M. Rowland, F. D. Kolodgie, M. B. Leon, and R. Virmani. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc. Interv. 3:68–75, 2010.
Natsuaki, M., K. Kozuma, T. Morimoto, K. Kadota, T. Muramatsu, Y. Nakagawa, T. Akasaka, K. Igarashi, K. Tanabe, Y. Morino, T. Ishikawa, H. Nishikawa, M. Awata, M. Abe, H. Okada, Y. Takatsu, N. Ogata, K. Kimura, K. Urasawa, Y. Tarutani, N. Shiode, and T. Kimura. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J. Am. Coll. Cardiol. 62:181–190, 2013.
Ng, X. W., Y. Huang, H. H. Chen, J. C. Burnett, F. Y. C. Boey, and S. S. Venkatraman. Cenderitide-eluting film for potential cardiac patch applications. PLoS One 8:e68346, 2013.
Ng, X. W., Y. Huang, K. L. Liu, F. Y. Boey, and S. S. Venkatraman. Investigation of cenderitide controlled release platforms for potential local treatment of cardiovascular pathology. J. Pharm. Sci. 103:1400–1410, 2014.
Ng, X. W., Y. Huang, K. L. Liu, S. G. Lim, H. H. Chen, J. C. Burnett, Jr, Y. C. Freddy Boey, and S. S. Venkatraman. In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach. J. Pharm. Sci. 103:3631–3640, 2014.
Nishikimi, T., N. Maeda, and H. Matsuoka. The role of natriuretic peptides in cardioprotection. Cardiovasc. Res. 69:318–328, 2006.
Pandey, K. N. Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulation. J. Am. Soc. Hypertens. 2:210–226, 2008.
Rogers, C., F. G. P. Welt, M. J. Karnovsky, and E. R. Edelman. Monocyte recruitment and neointimal hyperplasia in rabbits—coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol. 16:1312–1318, 1996.
Schwartz, R. S., N. A. Chronos, and R. Virmani. Preclinical restenosis models and drug-eluting stents still important, still much to learn. J. Am. Coll. Cardiol. 44:1373–1385, 2004.
Schwartz, R. S., and E. R. Edelman. Drug-eluting Stents in preclinical studies—recommended evaluation from a consensus group. Circulation 106:1867–1873, 2002.
Schwartz, R. S., K. C. Huber, J. G. Murphy, W. D. Edwards, A. R. Camrud, R. E. Vlietstra, and D. R. Holmes. Restenosis and the proportional neointimal response to coronary-artery injury—results in a porcine model. J. Am. Coll. Cardiol. 19:267–274, 1992.
Scotland, R. S., A. Ahluwalia, and A. J. Hobbs. C-type natriuretic peptide in vascular physiology and disease. Pharmacol. Ther. 105:85–93, 2005.
Shinomiya, M., J. Tashiro, Y. Saito, S. Yoshida, M. Furuya, N. Oka, S. Tanaka, K. Kangawa, and H. Matsuo. C-type natriuretic peptide inhibits intimal thickening of rabbit carotid artery after balloon catheter injury. Biochem. Biophys. Res. Commun. 205:1051–1056, 1994.
Stone, G. W., J. W. Moses, S. G. Ellis, J. Schofer, K. D. Dawkins, M. C. Morice, A. Colombo, E. Schampaert, E. Grube, A. J. Kirtane, D. E. Cutlip, M. Fahy, S. J. Pocock, R. Mehran, and M. B. Leon. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356:998–1008, 2007.
Suzuki, T., G. Kopia, S. Hayashi, L. R. Bailey, G. Llanos, R. Wilensky, B. D. Klugherz, G. Papandreou, P. Narayan, M. B. Leon, A. C. Yeung, F. Tio, P. S. Tsao, R. Falotico, and A. J. Carter. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188–1193, 2001.
Tsimikas, S. Drug-eluting stents and late adverse clinical outcomes: lessons learned, lessons awaited. J. Am. Coll. Cardiol. 47:2112–2115, 2006.
Venkatraman, S., and F. Boey. Release profiles in drug-eluting stents: Issues and uncertainties. J Control Release 120:149–160, 2007.
Welt, F. G. P., E. R. Edelman, D. I. Simon, and C. Rogers. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler. Thromb. Vasc. Biol. 20:2553–2558, 2000.
Woodard, G. E., and J. A. Rosado. Chapter 3 natriuretic peptides in vascular physiology and pathology. In: International Review of Cell and Molecular Biology, edited by W. J. Kwang. Waltham: Academic Press, 2008, pp. 59–93.
Woodard, G. E., and J. A. Rosado. Natriuretic peptides in vascular physiology and pathology. Int. Rev. Cell Mol. Biol. 268:59–93, 2008.
Acknowledgment
This work was supported by a grant from The National Research Foundation – Competitive Research Programme, http://www.nrf.gov.sg/(NRF-CRP 2-2007-01).
Author information
Authors and Affiliations
Corresponding author
Additional information
Associate Editor Sean McGinty oversaw the review of this article.
Rights and permissions
About this article
Cite this article
Huang, Y., Ng, X.W., Lim, S.G. et al. In vivo Evaluation of Cenderitide-Eluting Stent (CES) II. Ann Biomed Eng 44, 432–441 (2016). https://doi.org/10.1007/s10439-015-1389-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10439-015-1389-1